U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology
August 25 2022 - 6:00AM
Nuwellis, Inc. (Nasdaq: NUWE) a commercial stage company dedicated
to transforming the lives of patients suffering from fluid
overload, today announced that it was awarded a patent from the
United States Patent and Trademark Office for a novel innovation
that provides for improved fluid balance and safety in pediatric
dialysis and hemofiltration.
“We continue to invest in technological advancements that have a
meaningful impact for patients and clinicians,” said Nestor
Jaramillo, Jr., President and CEO of Nuwellis. “Clinicians
rely on us to provide advanced technology that affords them with
the flexibility to safely and easily expand treatment options for
their young patients. We are pleased to have received a patent for
this novel innovation that can enhance current and future
technology development initiatives.”
The novel innovations included in this patent will provide
healthcare providers with the ability to sense pressure changes in
the function of externally connected pumps so clinicians can make
any necessary therapeutic modifications.
Nuwellis is currently developing a new, fully integrated
pediatric continuous renal replacement therapy (CRRT) device
designed to provide care for small babies and children. This device
is funded in part by a $1.7 million grant from
the National Institutes of Health (NIH). The company has
partnered with Minneapolis-based research and development
firm Koronis Biomedical Technologies Corporation (KBT),
the grant recipient, in the design and development of a custom
pediatric product that will enable clinicians to better care for
babies with limited kidney function.
About NuwellisNuwellis, Inc. (Nasdaq:
NUWE) is a medical device company dedicated to transforming the
lives of patients suffering from fluid overload through science,
collaboration, and innovation. The Company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow® system for ultrafiltration therapy. Nuwellis is
headquartered in Minneapolis, with a wholly-owned subsidiary
in Ireland.
About the Aquadex SmartFlow® SystemThe Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and predictable method of removing excess fluid from
patients suffering from hypervolemia (fluid overload). The Aquadex
SmartFlow system is indicated for temporary (up to 8 hours) or
extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
Forward-Looking StatementsCertain statements in
this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the new
market opportunities and anticipated growth in 2022 and beyond.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our ability to execute on our commercialization strategy, the
impact of the COVID-19 pandemic, the possibility that we may be
unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities,
benefits of our products to patients, our expectations with respect
to product development and commercialization efforts, our ability
to increase market and physician acceptance of our products,
potentially competitive product offerings, intellectual property
protection, our ability to integrate acquired businesses, our
expectations regarding anticipated synergies with and benefits from
acquired businesses, and other risks and uncertainties described in
our filings with the SEC. Forward-looking statements speak
only as of the date when made. Nuwellis does not assume any
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
George Montague, CFA
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.Bacso@gilmartinir.com
MEDIA:
Sarah Lundberg
Health+Commerce
sarahlundberg@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024